Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. AroCell AB (publ)
  6. Summary
    AROC   SE0003883990

AROCELL AB (PUBL)

(AROC)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 12/07 10:53:34 am
1.326 SEK   -7.66%
12/03CORRECTION : AroCell nomination committee for the AGM 2022
AQ
12/03AroCell nomination committee for the AGM 2022
AQ
11/17New distributor agreement in the UK
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
1.452(c) 1.41(c) 1.412(c) 1.436(c) 1.326 Last
1 087 230 980 528 925 090 261 579 964 317 Volume
-1.09% -2.89% +0.14% +1.70% -7.66% Change
More quotes
Estimated financial data (e)
Sales 2020
Net income 2020
Net Debt 2020
P/E ratio 2020
Yield 2020
Sales 2021 23,0 M 2,53 M 2,53 M
Net income 2021 - - -
Net cash position 2021 22,0 M 2,42 M 2,42 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 165 M 18,1 M 18,1 M
EV / Sales 2020
EV / Sales 2021 6,20x
Nbr of Employees -
Free-Float 56,2%
More Financials
Company
AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company... 
More about the company
All news about AROCELL AB (PUBL)
12/03CORRECTION : AroCell nomination committee for the AGM 2022
AQ
12/03AroCell nomination committee for the AGM 2022
AQ
11/17New distributor agreement in the UK
AQ
11/17Arocell AB Announces New Distributor Agreement in the Uk
CI
11/12AroCell AB (publ) Interim Report January 1st to September 30th, 2021
AQ
11/12AroCell AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septemb..
CI
11/02New results with TK 210 ELISA support early therapy response in breast cancer
AQ
11/02New published analysis by Redeye
AQ
11/02AroCell - A Closer Look at the Acquisition
AQ
10/06AROCELL : updated strategy after the merger with IDL Biotech
PU
10/06AROCELL : updated strategy after the merger with IDL Biotech
AQ
10/06AROCELL AB (OM : AROC) completed the acquisition of IDL Biotech AB.
CI
08/31AROCELL AB (PUBL) : Interim Report January 1st to June 30th, 2021
AQ
08/31Arocell AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/25AROCELL : Elevated levels of serum TK1 in Hodgkin Lymphoma patients
AQ
More news
News in other languages on AROCELL AB (PUBL)

- No features available -

More news
Chart AROCELL AB (PUBL)
Duration : Period :
AroCell AB (publ) Technical Analysis Chart | AROC | SE0003883990 | MarketScreener
Technical analysis trends AROCELL AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 1,44 SEK
Average target price 3,50 SEK
Spread / Average Target 144%
Managers and Directors
Anders Hultman Chief Executive Officer
Claes Tomas Post Chairman
Kiran Kumar Jagarlamudi Research Director
Gunnar Steineck Chief Medical Officer
Agneta Franksson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AROCELL AB (PUBL)-38.63%18
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-42.48%23 888